Silence Therapeutics (NASDAQ:SLN) Sees Volume Increase Significantly

Silence Therapeutics plc (NASDAQ:SLN – Get Free Report) saw heavy trading volume on Thursday. 98,925 shares traded hands during trading, down 49% from the previous session’s volume of 195,111 shares. The stock last traded at $19.06 and had previously closed at $18.31.

Analyst upgrades and downgrades

Several equity research analysts have recently commented on the stock. Chardan Capital increased their price target on shares of Silence Therapeutics from $42.00 to $55.00 and gave the company a buy rating in a report on Friday. HC Wainwright reiterated its Buy rating and set a $75.00 price target on shares of Silence Therapeutics in a report Thursday. Finally, Morgan Stanley increased its price target on shares of Silence Therapeutics from $45.00 to $49.00 and gave the company an overweight rating in a report on Friday.

Get our latest research report on Silence Therapeutics

Silence Therapeutics Stock Performance

The stock’s 50-day moving average is $21.15 and its 200-day moving average is $20.95.

Silence Therapeutics (NASDAQ:SLN – Get Free Report) released its quarterly results on Thursday, May 16th. The company reported earnings per share of $(0.05) for the quarter, beating analysts’ consensus estimates of $(0.23) by $0.18. The company had revenue of $15.73 million for the quarter, compared to the consensus estimate of $4.53 million. Silence Therapeutics had a negative net margin of 131.44% and a negative return on equity of 79.90%. On average, stock analysts expect Silence Therapeutics plc to post EPS of -1.52 for the current year.

Institutional inputs and outputs

Several institutional investors have recently increased or reduced their stakes in the company. Redmile Group LLC purchased a new position in Silence Therapeutics during the first quarter worth approximately $43,798,000. Vivo Capital LLC increased its position in Silence Therapeutics by 116.7% in the first quarter. Vivo Capital LLC now owns 1,105,454 shares of the company’s stock worth $23,878,000 after acquiring an additional 595,250 shares during the period. Janus Henderson Group PLC purchased a new position in Silence Therapeutics during the first quarter worth approximately $13,575,000. Lynx1 Capital Management LP increased its position in Silence Therapeutics by 123.4% in the first quarter. Lynx1 Capital Management LP now owns 526,642 shares of the company’s stock worth $11,375,000 after acquiring an additional 290,855 shares during the period. Finally, Parkman Healthcare Partners LLC increased its position in Silence Therapeutics by 20.8% during the fourth quarter. Parkman Healthcare Partners LLC now owns 232,942 shares of the company’s stock worth $4,046,000 after acquiring an additional 40,063 shares during the period. 98.73% of shares are currently owned by institutional investors.

Silence Therapeutics Company Profile

(Get Free Report)

Silence Therapeutics plc, a biotechnology company, is focused on the discovery and development of novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in the areas of hematology, cardiovascular disease and rare diseases. The company’s mRNAi GalNAc oligonucleotide discovery platform consists of product candidates precisely designed to target specific disease-associated genes in the liver.

Learn more

Receive daily news and reviews from Silence Therapeutics – Enter your email address below to receive a concise daily summary of the latest news and analyst ratings for Silence Therapeutics and associated companies with MarketBeat.com’s FREE daily newsletter.